Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
Industry Legend Brings Deep Biotechnology Expertise
LA JOLLA, Calif., April 1, 2013
LA JOLLA, Calif., April 1, 2013 /PRNewswire/ --Regulus Therapeutics Inc.
(NASDAQ: RGLS), a biopharmaceutical company leading the discovery and
development of innovative medicines targeting microRNAs, announced today that
it has appointed William H. Rastetter, Ph.D. to its Board of Directors
"We are extremely pleased to have Bill join our Board," said John Maraganore,
Ph.D., Chairman of the Board of Directors of Regulus and CEO of Alnylam
Pharmaceuticals, Inc. "Bill is an industry legend who has invented, developed
and commercialized highly transformative therapies.He will be a valuable
resource as we continue to grow the company and develop first-in-class
medicines targeting microRNAs."
"Regulus' approach to treating complex, multi-factorial diseases by targeting
microRNAs is very exciting," said Dr. Rastetter. "I believe that Regulus'
therapeutic platform has significant scientific and commercial potential and I
look forward to collaborating with the Regulus team and Board of Directors to
realize the power of microRNA therapeutics."
Dr. Rastetter served as Chief Executive Officer of IDEC Pharmaceuticals from
December 1986 through November 2003, and as Chairman from May 1996 to November
2003. Upon the merger of IDEC Pharmaceuticals and Biogen in November 2003,
Dr. Rastetter served as Executive Chairman of Biogen Idec until the end of
2005.From 2006 to 2013, Dr. Rastetter served as a partner in the venture
capital firm, Venrock. Dr. Rastetter currently serves as the Chairman of the
Board of Directors of Fate Therapeutics, Inc., Illumina, Inc., Neurocrine
Biosciences and Receptos, Inc. He is the author of numerous scientific papers
and patent applications in the fields of organic and bioorganic chemistry,
protein and enzyme engineering, and biotechnology. Dr. Rastetter holds a S.B.
in Chemistry from the Massachusetts Institute of Technology and received his
M.A. and Ph.D. in Chemistry from Harvard University.
Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company
leading the discovery and development of innovative medicines targeting
microRNAs. Regulus is leveraging a mature therapeutic platform based on
technology that has been developed over 20 years. Regulus works with a broad
network of academic collaborators and leverages the oligonucleotide drug
discovery and development expertise of its founding companies, Alnylam
Pharmaceuticals and Isis Pharmaceuticals. Regulus is advancing microRNA
therapeutics toward clinical development in several areas, including oncology,
fibrosis, hepatitis C and metabolic diseases. Regulus has formed strategic
alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a research
collaboration with Biogen Idec.
For more information, please visit http://www.regulusrx.com.
Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements
associated with Regulus' expectations regarding future therapeutic and
commercial potential of Regulus' business plans, technologies and intellectual
property related to microRNA therapeutics being discovered and developed by
Regulus. Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or implied by such
forward-looking statements. Words such as "believes," "anticipates," "plans,"
"expects," "intends," "will," "goal," "potential" and similar expressions are
intended to identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be incorrect. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of various risks
and uncertainties, which include, without limitation, risks associated with
the process of discovering, developing and commercializing drugs that are safe
and effective for use as human therapeutics, and in the endeavor of building a
business around such drugs. These and other risks concerning Regulus'
programs are described in additional detail in Regulus' SEC filings. All
forward-looking statements contained in this press release speak only as of
the date on which they were made. Regulus undertakes no obligation to update
such statements to reflect events that occur or circumstances that exist after
the date on which they were made.
SOURCE Regulus Therapeutics Inc.
Contact: Amy Conrad, Director, Investor Relations and Corporate
Communications, Regulus Therapeutics Inc., 858-202-6300,
firstname.lastname@example.org, or Media: David Schull, Russo Partners LLC,
Press spacebar to pause and continue. Press esc to stop.